Abivax slides as traders digest recent trial updates and potential selling from a fresh ADS deal

Abivax S.A. (ABVX) is down 23.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to high biotech volatility around Abivax’s recent ulcerative colitis (UC) updates, with the stock potentially giving back gains as near-term positioning unwinds. This could also be because additional shares tied to a recently priced ADS transaction and related resale registration created incremental selling pressure.

Details:

Abivax recently posted first-quarter 2026 financial results and shared three-year interim data from Study 108, an open-label extension evaluating obefazimod in UC, keeping investor focus on durability and upcoming catalysts.

The company has highlighted that its ongoing Phase 3 UC maintenance study remains a key upcoming readout, which can amplify day-to-day swings as traders reprice perceived clinical risk.

In early May, Abivax announced a transaction to repurchase royalty certificates that was paired with the pricing of a $45 million offering of ADSs, a structure that can increase near-term float and trading supply.

A subsequent prospectus filing registered the potential offer and resale of up to 403,347 ADSs by selling shareholders, which may have contributed to market concern about additional distribution into strength.

Sources:

Abivax (Investor Relations), SEC (EDGAR), Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive ABVX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ABVX Hedge Fund Activity

We have seen 160 institutional investors add shares of $ABVX stock to their portfolio, and 132 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

POINT72 ASSET MANAGEMENT, L.P. removed 1,771,418 shares (-73.5%) from their portfolio in Q1 2026, for an estimated $197,247,394
MORGAN STANLEY removed 1,447,036 shares (-45.9%) from their portfolio in Q1 2026, for an estimated $161,127,458
DEUTSCHE BANK AG\ removed 764,899 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $85,171,503
FAIRMOUNT FUNDS MANAGEMENT LLC removed 713,434 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $96,210,142
PARADIGM BIOCAPITAL ADVISORS LP removed 645,000 shares (-45.5%) from their portfolio in Q1 2026, for an estimated $71,820,750
TCG CROSSOVER MANAGEMENT, LLC removed 630,511 shares (-8.9%) from their portfolio in Q1 2026, for an estimated $70,207,399
CORMORANT ASSET MANAGEMENT, LP removed 590,000 shares (-43.7%) from their portfolio in Q1 2026, for an estimated $65,696,500

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABVX Analyst Ratings

Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/25/2026
Citizens issued a "Market Outperform" rating on 12/16/2025

To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.

$ABVX Price Targets

Multiple analysts have issued price targets for $ABVX recently. We have seen 7 analysts offer price targets for $ABVX in the last 6 months, with a median target of $145.0.

Here are some recent targets:

Jason N. Butler from Citizens set a target price of $131.0 on 05/26/2026
Etzer Darout from Barclays set a target price of $148.0 on 03/24/2026
Faisal Khurshid from Jefferies set a target price of $160.0 on 03/16/2026
Julian Harrison from BTIG set a target price of $150.0 on 02/25/2026
David Nierengarten from Wedbush set a target price of $110.0 on 02/24/2026
Judah Frommer from Morgan Stanley set a target price of $145.0 on 01/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.